G-CSF Treatment for Amyotrophic Lateral Sclerosis: A RCT Study Assessing Clinical Response
Status:
Completed
Trial end date:
2007-08-01
Target enrollment:
Participant gender:
Summary
This study will examine the effectiveness of G-CSF in treating patients with amyotrophic
lateral sclerosis (ALS) - a fatal neurological degenerative disease that causes adult-onset,
progressive motor neurons loss in the spinal cord, brain stem and motor cortex. Patients
develop progressive wasting and weakness of both upper and lower limbs, bulbar and
respiratory muscles. Usually death from respiratory failure typically is within 3-5 years of
diagnosis. Although there are various treatments for ALS, riluzole is the only approved
treatment to delay the disease progression. G-CSF is an approved drug that is used to
increase white blood cell counts. Moreover, G-CSF and its receptor are expressed by neurons.
It acts anti-apoptosis by activating several protective pathways, stimulates neuronal
differentiation of adult neural stem cells in the brain, and improves long-term recovery.
G-CSF is a novel neurotrophic factor, and a highly attractive candidate for the treatment of
neurodegenerative conditions such as ALS.
Patients 18 to 65 years of age who have had mild to moderately severe ALS for 0.5 to 2 years
of duration may be eligible for this study. Candidates will be screened with a medical
history and possible review of medical records, physical examination, blood test, urine and
stool analyses, electrocardiogram, electrophysiological examination, neurological imaging
and, for women, a pregnancy test.
Participants will have drug therapy according to randomized number. One group receives G-CSF
while other group receives placebo. All of the participants receive riluzole treatment. For
the procedure, patients are given a medication to lessen anxiety and any discomfort. Patients
receive drug injections every 3 months for 5 days. The G-CSF dosage is 5μg/kg/day. Physical
examination and interview, Appel ALS scale and ALS-Functional Rating Scale will be done in
14, 28 days and 3, 6, 9, 12 months. Electrophysiological examination will be tested per 3
months. Blood samples will be collected on treat 5, 14, 28 days and 3, 6, 9, 12 months.